Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
749.48
-1.09 (-0.15%)
Apr 20, 2026, 12:25 PM EDT - Market open
Regeneron Pharmaceuticals Revenue
In the year 2025, Regeneron Pharmaceuticals had annual revenue of $14.34B with 0.99% growth. Regeneron Pharmaceuticals had revenue of $3.88B in the quarter ending December 31, 2025, with 2.51% growth.
Revenue (ttm)
$14.34B
Revenue Growth
+0.99%
P/S Ratio
5.37
Revenue / Employee
$930,753
Employees
15,410
Market Cap
76.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.34B | 140.90M | 0.99% |
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | 6.56B | 1.41B | 27.44% |
| Dec 31, 2018 | 5.15B | -726.60M | -12.37% |
| Dec 31, 2017 | 5.87B | 1.01B | 20.82% |
| Dec 31, 2016 | 4.86B | 756.67M | 18.44% |
| Dec 31, 2015 | 4.10B | 1.28B | 45.55% |
| Dec 31, 2014 | 2.82B | 714.81M | 33.96% |
| Dec 31, 2013 | 2.10B | 726.27M | 52.69% |
| Dec 31, 2012 | 1.38B | 932.66M | 209.20% |
| Dec 31, 2011 | 445.82M | -13.25M | -2.89% |
| Dec 31, 2010 | 459.07M | 79.81M | 21.04% |
| Dec 31, 2009 | 379.27M | 140.81M | 59.05% |
| Dec 31, 2008 | 238.46M | 113.43M | 90.73% |
| Dec 31, 2007 | 125.02M | 61.58M | 97.05% |
| Dec 31, 2006 | 63.45M | -2.75M | -4.15% |
| Dec 31, 2005 | 66.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vertex Pharmaceuticals | 12.00B |
| BeOne Medicines AG | 5.34B |
| argenx SE | 4.24B |
| Alnylam Pharmaceuticals | 3.71B |
| BioNTech SE | 3.37B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
| Insmed | 606.42M |
REGN News
- 7 days ago - Regeneron and Telix Announce Strategic Radiopharma Collaboration - GlobeNewsWire
- 7 days ago - Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) - GlobeNewsWire
- 7 days ago - Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - GlobeNewsWire
- 17 days ago - Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions - GlobeNewsWire
- 17 days ago - TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions - PRNewsWire
- 17 days ago - Regeneron says it expects to avoid new US pharma tariffs - Reuters
- 18 days ago - EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) - GlobeNewsWire
- 27 days ago - Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid - GlobeNewsWire